Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Overview
DESCRIPTION | |
Species Reactivity | Human. mouse, rat. Other species not tested. |
Immunogen | 158 aa recombinant protein from near the C terminal of human PDGF-C. |
Purification | Purified by peptide affinity column. |
Formulation | Lyophilized with 0.5% BSA and 0.02% NaN3. |
Size | 100ug/200µl |
APPLICATION | |
ELISA | 1:20,000 – 1:80,000 |
Western Blot | 1:200-1:1000 |
Immunohistochemistry | 1:50-1:200 |
For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. | |
PREPARATION AND STORAGE | |
Reconstitution | Reconstitute in 200µl of sterile H2O. |
Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
REFERENCES |
Crawford,Y., Kasman,I., Yu,L., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15 (1), 21-34 (2009. |